Dan O'Day, Gilead CEO (Jim Watson/AFP via Getty Images)
Failing to confirm clinical benefit, Gilead pulls 2 accelerated approval indications for cancer drug
Gilead recently decided to pull two indications for its cancer drug Zydelig — in relapsed follicular B-cell non-Hodgkin lymphoma (FL) and relapsed small lymphocytic leukemia …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.